StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money19.11.2026 18:01:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / November 19, 2026 / The Global Anti-Scam Alliance (GASA), in collaboration with Outseer, today released the Global State of Scams 2026 report. Based on a survey of 58,900 adults across 42 markets, the report examines how often people encounter scams, how they respond, and the financial and emotional impact on those affected. In the past 12 months, 64% of adults worldwide encountered a scam and 9% lost money. Shopping, investment, and unexpected money scams were among the types people most often interacted with. In Africa, 21% of adults lost money to a scam, more than double the global rate. The research also highlights the emotional toll of scams. Among people who lost money, 69% reported a significant or moderate impact on their mental wellbeing, 20% reported increased tension at home, and 16% said they could not pay for essentials such as rent or groceries. Among those who did not report the scam to an organization, the most common reason was uncerta
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself19.11.2026 15:00:00 CET | Press release
WARSAW, PL / ACCESS Newswire / November 19, 2026 / Polcode, a software development company that has helped businesses across North America and Europe modernize their technology since 2006, launched its new website at polcode.com this week. Timed to the company's 20th anniversary, the launch is more than a redesign. It applies the same modernization approach Polcode brings to client systems every day to its own brand. For 20 years, Polcode has been the team businesses call when software stops keeping up with the business: aging platforms, tangled integrations, and tools nobody dares touch. So when it came time to rebuild its own website, the question was fair. Would a company that modernizes for others hold itself to the same standard? The new site is Polcode's answer, serving as both a showcase of what the company does and an example of it. We spend a lot of time helping businesses move beyond systems that no longer reflect where they're headed. At some point, we had to ask ourselves t
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval19.11.2026 13:45:00 CET | Press release
CALGARY, AB / ACCESS Newswire / November 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has completed registration under the Compliance Instrument Tracking System Service (CITSS), enabling the Company to participate directly in California's regulated compliance carbon market. This milestone elevates Karbon-X's North American trading infrastructure, enabling the Company to directly source, hold, and transact compliance allowances and eligible offset credits, positioning the Company to capture trading margins and recurring commercial opportunities from California's ongoing compliance demand. Unlike voluntary carbon markets, California's Cap-and-Invest Program is backed by state regulation requiring covered entities to surrender eligible compliance instruments against their emissions obligations, creating recurring regulatory demand for allowances and eligible offset credits. California's pro
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor18.11.2026 15:30:00 CET | Press release
DETROIT, MI / ACCESS Newswire / November 18, 2026 / Leggett Dynamics has won a 2026 Automotive News PACE Pilot Award for its Smart Brushless Motor. This next-generation motion system simplifies vehicle integration, improves performance and supports the industry's transition to software-defined vehicles (SDVs). Leggett Dynamics' Smart Brushless Motor streamlines motion-control architecture by operating with or without a seat-level electronic control unit (ECU). The system enables direct communication between the vehicle-level ECU and individual actuators, supporting more centralized and zonal vehicle architectures while reducing packaging size, weight and wiring complexity. It also improves noise, vibration and harshness (NVH), durability, and electromagnetic compatibility (EMC). "As automakers transition to software-defined vehicles, they are looking for solutions that reduce complexity without compromising performance," said Julien Rea, VP of Global Innovation and Engineering at Legge
Proxymity Unveils MiKaDiv Compliance Solution for Issuers Ahead of New German Tax Regime18.11.2026 08:30:00 CET | Press release
FRANKFURT AM MAIN, DE / ACCESS Newswire / November 18, 2026 / Proxymity, the digital investor communications platform, is set to launch its MiKaDiv Compliance Solution as Germany's new dividend reporting regime takes effect in January 2027, giving German issuers a single place to manage their new obligations to the Federal Central Tax Office (BZSt). From 1 January 2027, dividends paid by listed German companies will carry an additional reporting step: the company must pass details of its shareholders to the BZSt. SRD II, transposed into German law under Section 67d of the German Stock Corporation Act, (AktG) took effect in 2020 and gave issuers the right to identify their investors, including foreign investors held through nominee accounts. MiKaDiv now makes it a requirement. The first reports are expected early in the 2027 AGM season, as issuers seek approval for their dividends. Proxymity is the leading provider of shareholder identification to German issuers, handling more than 40%
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
